Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(83.3%)

Phase 2

1(16.7%)

6Total

Phase 1(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05082831Phase 1Terminated

Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage

Role: lead

NCT02960204Phase 2Completed

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

Role: lead

NCT04803227Phase 1Terminated

Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19

Role: lead

NCT04435847Phase 1Completed

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Role: lead

NCT03662854Phase 1Unknown

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

Role: lead

NCT01501617Phase 1Unknown

Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia

Role: lead

All 6 trials loaded